enzon pharmaceuticals , inc is a pharmaceutical company engaged in developing therapeutics to patients whose needs are unmet .

its headquarters is now in piscataway , new jersey .

the company is a publicly traded company on nasdaq under the symbol " enzn " .

it 's also doing marketing works in asia areas such as china .

in 2012 , the company orally presented in nanjing , china about the symposium of its drug delivery systems , which help improve therapeutic molecules ' pharmaceutical properties .

enzon pharmaceuticals

enzon pharmaceuticals ' s revenue was reported to be $ 8 . 38 m in fy , 2016
enzon pharmaceuticals , inc . ’s iss governance qualityscore as of n / a is n / a .
note to media and investors belrose pharma has been formed by new investors to develop pharmaceutical products with technologies and clinical programs acquired from enzon pharmaceuticals and others . the belrose pharma investors have no substantive relationship to any major equity or debt holder in enzon pharmaceuticals . enzon pharmaceuticals also does not have any equity ownership in belrose pharma .
you are requesting a prediction for the closing price for enzon pharmaceuticals ( enzn ) for 2018 - 07 - 10 .
for enzon : andrea rabney argot partners 212 . 600 . 1902 email contact for hisun : zhang wei zhejiang hisun pharmaceuticals ( 86571 ) 8527 8141 email contact
after selling out in the second quarter , carl icahn ( trades , portfolio ) acquired an even larger position in enzon pharmaceuticals ( enzn ) on nov . 28 .
after selling out in the second quarter , carl icahn ( trades , portfolio ) acquired an even larger position in enzon pharmaceuticals ( enzn ) on nov . 28 .
enzon pharmaceuticals , inc . manages its sources of royalty revenues from existing licensing arrangements with other companies primarily related to sales of certain drug products that utilize our proprietary technology .
genzyme is the biotech industry’s second - largest company , with revenues of $ 4 . 5 billion and a market capitalization of about $ 13 billion . previously , mr . icahn has taken on smaller companies : biogen - idec , medimmune , imclone systems , amylin pharmaceuticals and enzon pharmaceuticals .
enzon pharmaceuticals , inc . is a biotechnology company dedicated to the research and development of innovative therapeutics for patients with high unmet medical need . enzon’s drug - development programs utilize two platforms : customized pegylation linker technology ( customized linker technology® ) and third - generation mrna - targeting agents utilizing the locked nucleic acid ( lna ) technology . enzon currently has four compounds in human clinical development and multiple novel mrna antagonists in preclinical research . enzon receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its proprietary customized linker technology . further information about enzon and this press release can be found on the company’s website at urltoken .
new york , ny / accesswire / march 5 , 2018 / latest key findings by growth market report for all traders , shareholders , and investors of vet online supply , inc . ( otc pink : vtnl ) and enzon pharmaceuticals . . .
enzon pharmaceuticals , inc . is a biopharmaceutical company , which engages in the provision of licensing arrangements related to sales of drug products that utilize its proprietary technology . the company was founded on september 17 , 1981 and is headquartered in cranford , nj .
craig brings a wealth of knowledge and experience to enzons executive management team ,  said jeffrey h . buchalter , enzons chairman and chief executive officer . i am confident his extensive industry experience across multiple disciplines will be an invaluable asset as we define and execute our strategy for driving enzon to its next stage of growth .
piscataway , nj and zhejiang , china — ( marketwire ) — 05 / 07 / 12 — enzon pharmaceuticals , inc . ( nasdaq : enzn ) and zhejiang hisun pharmaceuticals co . ltd ( sse code : 600267 ) , a leading chinese pharmaceutical company , announced today a long - term strategic research , development and licensing collaboration . the agreement provides for the research and development of therapeutics using enzon’s customized pegylation linker technology . the agreement also includes the license to hisun of development and commercialization rights for enzon’s peg - sn38 ( ezn - 2208 ) , a novel , phase ii pegylated version of sn38 , in the territory of china .
bridgewater , new jersey , january 5 , 2005  enzon pharmaceuticals , inc . ( nasdaq : enzn ) today announced that craig tooman has been appointed executive vice president strategic planning and corporate communications . mr . tooman will report to enzons chairman and chief executive officer , jeffrey buchalter , and joins mr . buchalter and kenneth zuerblis , enzons executive vice president finance and chief financial officer , as an executive officer of the company . he will oversee enzons public relations , investor relations , and strategic planning functions . prior to joining enzon , mr . tooman served as senior vice president , strategic planning and corporate communications of ilex oncology , inc . , which was acquired by genzyme corporation ( nasdaq : genz ) in december 2004 .
enzon pharmaceuticals , inc . , together with its subsidiaries , engages in licensing drug products . its marketed drug products include pegintron for use in the treatment of chronic hepatitis c ; and sylatron for use in the treatment of melanoma disease . the company was founded in 1981 and is headquartered in cranford , new jersey .
meanwhile , two smaller biotechnology companies , enzon and amylin , have also experienced mr . icahn’s challenges . since he urged the spinoff of enzon’s biotechnology business in 2007 , mr . icahn has been successful in adding two directors and dr . denner was elected chairman of enzon’s board . at amylin , its chief executive , joseph cook , was forced out in 2009 after mr . icahn won two board seats .
enzon pharmaceuticals is a biopharmaceutical company dedicated to the discovery , development , and commercialization of therapeutics to treat life - threatening diseases . the company has developed or acquired a number of marketed products , including peg - intron ( r ) , marketed by schering - plough , and abelcet ( r ) , oncaspar ( r ) , adagen ( r ) , and depocyt ( r ) , marketed in north america by enzons specialized sales force . enzons science - driven strategy includes an extensive drug development program that leverages the companys macromolecular engineering technology platforms , including peg modification and single - chain antibody ( sca ( r ) ) technologies . internal research and development efforts are complemented by strategic transactions that provide access to additional marketed products and promising clinical compounds . enzon has several drug candidates in various stages of development , independently and with partners . further information about enzon can be found on the companys web site at urltoken .
enzon pharmaceuticals has pegged its future on researching ways to fight cancer . the company is focused on developing compounds using its pegylation technology and other platforms to improve the performance and deliverability of existing cancer drugs . pegylation involves custom attaching polyethylene glycol ( peg ) to a drug compound in order to make it more effective and less toxic for patients . . . .
enzon pharmaceuticals is the lower part of a horizontal trend on short term , and normally this would pose a good buying opportunity , though a break down through the bottom trend line at $ 0 . 26 will give a strong sales signal and a trend shift may be expected . given the current horizontal trend you can expect enzon pharmaceuticals with 90 % probability to be traded between $ 0 . 26 and $ 0 . 28 at the end of this period with 90 % probability . a break of a horizontal trend is often followed by a large increase in the volume , and stocks seldom manage to go directly from the bottom of a trend up to the roof . stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners .
while the company delisted earlier this year , it is still available as an over - the - counter stock . on thursday , enzon closed at 45 cents .
enzon is a biotechnology company dedicated to the research and development of innovative therapeutics for cancer patients with high unmet medical needs . the original enzon mark was something that resembled a cell with tentacles and a logotype that was dated . a rebranding effort was needed . a more streamlined font would give enzon’s identity a more contemporary look . optima was that font . we customized the “e” by attaching it to the “n” to form a unified ligature for a more innovative appeal . developing pharmaceuticals that targeted the human cell was best represented by the “o” in the logotype . management suggested a mark that would portray a company that was on the move—agile and forward - looking . an arrowhead placed within the “o” effectively represented this idea .
“hisun is a dynamic company with an aggressive strategy for expanding its portfolio of innovative therapeutics . we are very excited about this partnership and we look forward to advancing a variety of next - generation therapeutics with hisun in china and for enzon in other territories around the world , ” said ana stancic , principal executive officer of enzon . “enzon’s broad portfolio of proprietary permanent and releasable pegylation linker technology and decades of know - how offer unmatched , clinically and commercially validated capabilities for the enhancement of existing therapies to create novel , high - value product candidates , including bio - betters . ”
, according to activist shareholders . honestly , i felt a little guilty last month for criticizing enzon ' s $ 250 , 000 to $ 500 , 000 per year price for ada - scid drug
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products , namely , pegintron® , sylatron® , macugen® and cimzia® . pegintron® is used for the treatment of chronic hepatitis c . sylatron® is used for the treatment of melanoma . macugen® is used for the treatment of neovascular ( wet ) age - related macular degeneration . cimzia® is used for the treatment of crohn ' s disease and rheumatoid arthritis . co . has no clinical operations and limited corporate operations .
subsequent to the completion of this acquisition , several members of the core technical team that was formerly involved in enzon’s extensive research , development , and commercialization of the permanent and releasable customized linker technology® have joined belrose pharma .
( pegadamase bovine ) after readers pointed out that as an ultra - orphan disease , enzon has to charge that much to make a profit . but maybe they could charge less if they reconsidered their executive pay policies .
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products , namely , pegintron® , sylatron® , macugen® and cimzia® . pegintron® is used for the treatment of chronic hepatitis c . sylatron® is used for the treatment of melanoma . macugen® is used for the treatment of neovascular ( wet ) age - related macular degeneration . cimzia® is used for the treatment of crohn ' s disease and rheumatoid arthritis . co . has no clinical operations and limited corporate operations . according to our enzn split history records , enzn has had 1 split .
enzon pharmaceuticals receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products , namely , pegintron , sylatron , macugen and cimzia . the primary source of the company’s royalty revenues is sales of pegintron , which is marketed by merck & co . the company currently has no clinical operations and limited corporate operations . the company was previously dedicated to the research and development of innovative therapeutics for patients with high unmet medical needs . the company wound down its remaining research and development activities during 2013 and has no intention of resuming any clinical development activities or acquiring new sources of royalty revenues .
such forward - looking statements are based upon management’s present expectations , objectives , anticipation , plans , hopes , beliefs , intentions or strategies regarding the future and are subject to known and unknown risks and uncertainties that could cause actual results , events or developments to be materially different from those indicated in such forward - looking statements . a more detailed discussion of these and other factors that could affect results is contained in enzon’s filings with the u . s . securities and exchange commission , including enzon’s annual report on form 10 - k for the year ended december 31 , 2011 . these factors should be considered carefully and readers are cautioned not to place undue reliance on such forward - looking statements . no assurance can be given that the future results covered by the forward - looking statements will be achieved . all information in this press release is as of the date of this press release and enzon does not intend to update this information .
management revealed it is expecting to receive a cumulative amount of $ 21 million in royalty revenues between the beginning of 2016 and 2021 . many expect the company to liquidate after this point . icahn may be interested in enzon for this very reason . the company already distributes special dividends throughout the year so its final liquidation may prove to be especially beneficial to shareholders .
under the terms of the strategic research , development and licensing collaboration , hisun will pay enzon to apply its customized pegylation linker technology , especially its releasable pegylation technology , and know - how to the development of next - generation , pegylated versions of select therapeutic candidates within hisun’s pipeline . once successfully pegylated , hisun will have the option to in - license the product candidates , based upon internal selection criteria , and will be fully responsible for funding development and commercialization of these products in the territory of china . under this agreement , enzon is entitled to milestone payments and a high - single - digit royalty on net sales for any product developed and commercialized in china , in addition to retaining rights to all pegylated compounds outside of china .
enzon is actively pursuing strategic partnerships with leading biotechnology and pharmaceutical companies worldwide whose marketed , development , or discovery - stage products may benefit from the enhanced pharmaceutical properties of pegylation . “our pegylation platform , combined with our extensive know - how , continues to be the gold standard for maximizing the therapeutic potential of both small molecules and biologics , ” says ms . stancic .
belrose will leverage the value of the assets purchased from enzon within belrose’s two key business areas : ( a ) advancing development of internal clinical and pre - clinical compounds , and ( b ) product development for third party customers seeking to improve both early clinical and mid - lifecycle products using customized linker technology® , where alternative technologies such as nanoparticles and lipid formulations are less suitable .
“this acquisition of enzon’s permanent and releasable customized linker technology® significantly strengthens our platform for accelerating the development of more patient - friendly and effective therapies in a range of specialty disease categories , ” said belrose pharma founder and ceo , eric gilbert . “we look forward to being a positive force for bringing new therapies and improved formulations of existing therapies to the global healthcare marketplace and to critically ill patient populations . ”
hua bai , ceo and chairman of hisun , added , “enzon’s pegylation technology is utilized in approved products generating a combined total of over $ 7 billion in annual sales , making them the partner of choice for validated pegylation technology . in addition to obtaining rights to peg - sn38 , this partnership provides hisun access to innovative technology and development capabilities that will allow us to deliver novel therapeutics to the rapidly growing pharmaceutical market in china . ”
enzon was formerly a research stage biopharmaceutical company known for its customized pegylation linker technology . pegylation is used in the development of drugs to improve characteristics like solubility , reduced dosage , stability and lower toxicity . it now has no clinical operations and very limited corporate operations . currently , it is surviving off royalty streams from products that incorporate this technology . these products include pegintron , sylatron , macugen and cimzia . the company also ran a products and manufacturing division but divested it in 2010 .
about pegylation technology pegylation technology has successfully enabled regulatory approval and launch of a series of breakthrough pharmaceutical products since enzon first pioneered the technique in the 1980s . since fda approval of the first pegylated product , adagen® ( peg - bovine adenosine deaminase ) in 1990 , cumulative worldwide revenue of all pegylated pharmaceutical products has exceeded $ 20 billion . pegylation has been validated for compounds including enzymes , peptides , small molecules and antibody fragments , with the chemical attachment of polyethylene glycol ( peg ) used to improve those compounds’ half lives and toxicity profiles , among other patient benefits achieved by maximizing the inherent biological activity of the native molecules .
in contrast , enzon’s profitability and growth was ranked 4 of 10 by gurufocus . it has an operating margin of 78 . 3 % and a net margin of 149 . 6 % . the return on equity ( roe ) and return on assets ( roa ) outperform 99 % of other biotechnology companies . the return on capital ( roc ) outperforms 100 % of competitors . where the company falls short is its three - year revenue growth of - 24 . 3 % . this figure underperforms 76 % of competitors . additionally , the company has a one - star predictability rating , which means it is hard to predict future results .
princeton , nj , june 19 , 2013 – in its first major deal , belrose pharma , a new specialty pharmaceutical company dedicated to advancing development of the next generation of innovative injectable and sustained release drug therapies in patient disease populations with high unmet medical needs , today announced the acquisition of enzon pharmaceutical’s pegylation linker technology ( customized linker technology® ) platform and associated product pipeline . acquisition of this technology will enable belrose pharma to accelerate creation of improved biologic and small molecule therapies with better treatment outcomes for patients with life - threatening diseases such as breast cancer and pediatric neuroblastoma , and orphan drug diseases such as hereditary angioedema ( hae ) .
in contrast , enzon ' s profitability and growth was ranked 4 of 10 by gurufocus . it has an operating margin of 78 . 3 % and a net margin of 149 . 6 % . the return on equity ( roe ) and return on assets ( roa ) outperform 99 % of other biotechnology companies . the return on capital ( roc ) outperforms 100 % of competitors . where the company falls short is its three - year revenue growth of - 24 . 3 % . this figure underperforms 76 % of competitors . additionally , the company has a one - star predictability rating , which means it is hard to predict future results .
dr . kostas has been a director of our company since september 25 , 2013 . since january 2016 , dr . kostas has been a senior analyst at sarissa capital management lp , an investment firm focused on the health care industry . prior to joining sarissa capital management lp , dr . kostas covered the biotechnology and pharmaceutical industries , most recently as director , at evercore isi ( formerly known as international strategy & investment ) , a full service broker - dealer that provides macro and fundamental research , sales , and trading services to customers . previously , he practiced internal medicine as part of the yale new haven health system and was engaged as a consultant to various biotechnology companies . in addition , from 2010 to 2011 , dr . kostas served as a member of the board of directors of mast therapeutics ( then known as adventrx pharmaceuticals ) . dr . kostas received his s . b . degree from the massachusetts institute of technology and his m . d . degree from the university of texas southwestern medical school .
hisun has also acquired exclusive development and commercialization rights to peg - sn38 in china and will pay enzon an undisclosed upfront fee , milestone payments and a high - single - digit royalty on net sales . further financial terms were not disclosed . peg - sn38 has completed phase ii clinical trials in the united states where it was studied as a treatment for metastatic breast cancer , colorectal cancer and solid tumors in pediatric cancer patients . it is a pegylated conjugate of sn38 , the active metabolite of the widely used anti - cancer drug irinotecan . peg - sn38 offers therapeutic advantages over unmodified sn38 , including increased solubility , higher exposure and tumor accumulation , more profound deoxyribonucleic acid ( dna ) damage , inhibition of angiogenesis and longer apparent half - life of sn38 as compared to irinotecan .
belrose will continue development of two programs acquired from enzon . the first program is peg - sn38 ( formerly ezn - 2208 ) , a phase iii - ready pegylated conjugate of sn38 with improved properties including parenteral delivery , increased solubility , higher exposure , more profound deoxyribonucleic acid ( dna ) damage , inhibition of angiogenesis , and longer half - life compared with native sn38 . peg - sn38 produced positive responses in clinical trials for metastatic breast cancer and pediatric neuroblastoma . the second program is peg - c1 esterase inhibitor ( formerly ezn - 3008 ) , a preclinical pegylated form of plasma - derived c1 - esterase inhibitor ( c1 - inh ) offering the significant improvement of weekly or bi - weekly subcutaneous or intravenous injections to hae patients currently limited to twice - weekly infusions for prophylactic use .
and compensation values are for the last fiscal year ending on that date . pay is salary , bonuses , etc . exercised is the value of options exercised during the fiscal year . currency in usd .
the pillar scores are audit : n / a ; board : n / a ; shareholder rights : n / a ; compensation : n / a .
scores indicate decile rank relative to index or region . a decile score of 1 indicates lower governance risk , while a 10 indicates higher governance risk .
jul 9 , 2018 1 : 35 pm edt . 15 minute delayed data provided by nasdaq
we ' re sorry this is all we were able to find about this topic .
html public
- / / w3c / / dtd xhtml 1 . 0 transitional / / en
urltoken
we ' re sorry we weren ' t able to find anything about this topic .
html public
- / / w3c / / dtd xhtml 1 . 0 strict / / en
urltoken
html public
- / / w3c / / dtd html 4 . 0 transitional / / en
urltoken
he bought 6 , 598 , 886 shares for an average cost of 41 cents per share . this represents nearly 15 % of the company’s outstanding shares but only accounts for 0 . 01 % of his total assets managed .
warning ! gurufocus has detected 2 warning signs with enzn . click here to check it out .
the new jersey - based biopharmaceutical company has a market cap of $ 19 . 9 million and an enterprise value of $ 7 . 12 million . it has a price - earnings ( p / e ) ratio of 1 . 4 , a price - book ( p / b ) ratio of 0 . 9 and a price - sales ( p / s ) ratio of 1 . 9 .
gurufocus ranked the company’s financial strength 8 of 10 . the piotroski f - score of 5 and altman z - score of 68 . 12 suggest the company is financially stable . the return on invested capital ( roic ) outperforms the weighted average cost of capital ( wacc ) so the company is creating value as it grows . in addition , the company has no debt .
the stock reached its all - time high of $ 77 . 94 in november of 2000 . since then , the stock has declined significantly . in april of 2002 , the stock was trading around $ 40 and fell to $ 28 . 73 by the end of may that same year . from there , the stock continued its gradual decline with only a few surges throughout the next several years . within the past six years , the highest price the stock has reached was $ 12 . 16 on dec . 31 , 2010 . it has been trading under $ 2 since august 2013 .
icahn has a long history with the company that dates back prior to the first quarter of 2010 .
disclosure : i do not own stock in any companies mentioned in the article .
i am an editorial assistant at gurufocus . i have a ba in journalism and a ma in mass communications from texas tech university . i have lived in texas most of my life , but also have roots in new mexico and colorado . follow me on twitter ! @ gurusydneeg
get wordpress plugins for easy affiliate links on stock tickers and guru names | earn affiliate commissions by embedding gurufocus charts gurufocus affiliate program : earn up to $ 400 per referral . ( learn more )
disclaimers : urltoken is not operated by a broker , a dealer , or a registered investment adviser . under no circumstances does any information posted on urltoken represent a recommendation to buy or sell a security . the information on this site , and in its related newsletters , is not intended to be , nor does it constitute , investment advice or recommendations . the gurus may buy and sell securities before and after any particular article and report and information herein is published , with respect to the securities discussed in any article and report posted herein . in no event shall urltoken be liable to any member , guest or third party for any damages of any kind arising out of the use of any content or other material published or available on urltoken , or relating to the use of , or inability to use , urltoken or any content , including , without limitation , any investment losses , lost profits , lost opportunity , special , incidental , indirect , consequential or punitive damages . past performance is a poor indicator of future performance . the information on this site , and in its related newsletters , is not intended to be , nor does it constitute , investment advice or recommendations . the information on this site is in no way guaranteed for completeness , accuracy or in any other way . the gurus listed in this website are not affiliated with urltoken , llc . stock quotes provided by interactive data . fundamental company data provided by morningstar , updated daily .
html public
- / / w3c / / dtd html 4 . 01 transitional / / en
urltoken
if the video does not load after a few moments , upgrade to the latest flash player .
nothing in dividend channel is intended to be investment advice , nor does it represent the opinion of , counsel from , or recommendations by bnk invest inc . or any of its affiliates , subsidiaries or partners . none of the information contained herein constitutes a recommendation that any particular security , portfolio , transaction , or investment strategy is suitable for any specific person . all viewers agree that under no circumstances will bnk invest , inc , . its subsidiaries , partners , officers , employees , affiliates , or agents be held liable for any loss or damage caused by your reliance on information obtained . by visiting , using or viewing this site , you agree to the following
enter up to 25 symbols separated by commas or spaces in the text box below . these symbols will be available during your session for use on applicable pages .
don ' t know the stock symbol ? use the symbol lookup tool . alphabetize the sort order of my symbols
sign up now to become a urltoken member and begin receiving instant notifications when key events occur that affect the stocks you follow .
the dividend history page provides a single page to review all of the aggregated dividend payment information . visit our dividend calendar : our partner , zacks investment research , provides the upcoming ex - dividend dates for the next month .
dividend history information is presently unavailable for this company . this could indicate that the company has never provided a dividend or that a dividend is pending .
please note that once you make your selection , it will apply to all future visits to nasdaq . com . if , at any time , you are interested in reverting to our default settings , please select default setting above . if you have any questions or encounter any issues in changing your default settings , please email isfeedback @ urltoken .
you have selected to change your default setting for the quote search . this will now be your default target page ; unless you change your configuration again , or you delete your cookies . are you sure you want to change your settings ?
please disable your ad blocker ( or update your settings to ensure that javascript and cookies are enabled ) , so that we can continue to provide you with the first - rate market news and data you ' ve come to expect from us .
html public
- / / w3c / / dtd html 4 . 01 transitional / / en
html public
- / / w3c / / dtd xhtml 1 . 0 strict / / en
urltoken
s & p 500 index data : s & p 500 copyright © 2018 currency is displayed in usd .
international sites : australia canada china france germany hong kong italy the netherlands norway spain u . k . switzerland
independent . insightful . trusted . morningstar provides stock market analysis ; equity , mutual fund , and etf research , ratings , and picks ; portfolio tools ; and option , hedge fund , ira , 401k , and 529 plan research . our reliable data and analysis can help both experienced enthusiasts and newcomers . © copyright morningstar , inc . all rights reserved . please read our terms of use and privacy policy . dow jones industrial average , s & p ; 500 , nasdaq , and morningstar index ( market barometer ) quotes are real - time . russell 2000 quote is 10 minutes delayed .
html public
- / / w3c / / dtd html 4 . 01 / / en
urltoken
copyright © quotemedia . data delayed 15 minutes unless otherwise indicated . view delay times for all exchanges . market data powered by quotemedia . see the quotemedia terms of use .
the overall rating is a weighted average of the three other rated categories listed below . it is a general indication of the health of a dividend .
this indicator measures a stock ' s current dividend yield , and compares it to similar stocks and historical yields .
the rating for dividend history is determined by looking back at the frequency and amount of historical dividend payments .
this indicator measures a stock ' s history of dividend increases ; consistent increases over time will produce a favorable rating .
information / data on this site is provided ' as is ' and for informational purposes only . please read our disclaimer and complete terms of use .
database . the split for enzn took place on september 29 , 2017 . this was a 5 for 3 split , meaning for each 3 shares of enzn owned pre - split , the shareholder now owned 5 shares . for example , a 1000 share position pre - split , became a 1666 . 66666666667 share position following the split .
when a company such as enzn splits its shares , the market capitalization before and after the split takes place remains stable , meaning the shareholder now owns more shares but each are valued at a lower price per share . often , however , a lower priced stock on a per - share basis can attract a wider range of buyers . if that increased demand causes the share price to appreciate , then the total market capitalization rises post - split . this does not always happen , however , often depending on the underlying fundamentals of the business . looking at the enzn split history from start to finish , an original position size of 1000 shares would have turned into 1666 . 66666666667 today . below , we examine the compound annual growth rate — cagr for short — of an investment into enzn shares , starting with a $ 10 , 000 purchase of enzn , presented on a split - history - adjusted basis factoring in the complete enzn split history .
enzn split history | www . split history . com | copyright © 2013 - 2018 , all rights reserved
is intended to be investment advice , nor does it represent the opinion of , counsel from , or recommendations by bnk invest inc . or any of its affiliates , subsidiaries or partners . split history database is not guaranteed to be complete or free of errors . none of the information contained herein constitutes a recommendation that any particular security , portfolio , transaction , or investment strategy is suitable for any specific person . all viewers agree that under no circumstances will bnk invest , inc , . its subsidiaries , partners , officers , employees , affiliates , or agents be held liable for any loss or damage caused by your reliance on information obtained . by visiting , using or viewing this site , you agree to the following
ms . mcnealey has been a director of our company since september 25 , 2013 . since december 2016 , ms . mcnealey has been vice president , investor relations and strategy of calithera biosciences , inc . from february 2015 to december 2016 , ms . mcnealey was senior director investor relations and serves as a member of the management team at calithera biosciences , inc . prior to joining calithera biosciences , inc . , ms . mcnealey served as an advisor to biotechnology companies . in 2005 , ms . mcnealey founded laurient llc , a research company focused on the biotechnology and pharmaceutical industries , where she worked until 2012 . prior to founding laurient llc , ms . mcnealey served as a portfolio manager and biotechnology analyst at various firms , including paramount capital , franklin templeton , amerindo investment advisors and morgan stanley dean witter advisors . ms . mcnealey has a b . a . and an m . h . a . from cornell university .
phone : 1 732 9804500 fax : 13 - 02 - 6555049 urltoken no . employees : 01 turnover : 08 . 38 ( us $ m ) financial year end : december
know more about this business than we do ? cool ! please submit any corrections or missing details you may have .
use of and / or registration on any portion of this site constitutes acceptance of our user agreement ( updated 5 / 25 / 18 ) and privacy policy and cookie statement ( updated 5 / 25 / 18 ) .
© 2018 advance local media llc . all rights reserved ( about us ) . the material on this site may not be reproduced , distributed , transmitted , cached or otherwise used , except with the prior written permission of advance local .
community rules apply to all content you upload or otherwise submit to this site .
legal status ( the legal status is an assumption and is not a legal conclusion . google has not performed a legal analysis and makes no representation as to the accuracy of the status listed . )
current assignee ( the listed assignees may be inaccurate . google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list . )
priority date ( the priority date is an assumption and is not a legal conclusion . google has not performed a legal analysis and makes no representation as to the accuracy of the date listed . )
chemical analysis of biological material , e . g . blood , urine ; testing involving biospecific ligand binding methods ; immunological testing
chemical analysis of biological material , e . g . blood , urine ; testing involving biospecific ligand binding methods ; immunological testing involving proteins , peptides or amino acids
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient , e . g . polymer - drug conjugates
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient , e . g . polymer - drug conjugates the non - active ingredient being a modifying agent
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient , e . g . polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound , e . g . an oligomeric , polymeric or dendrimeric molecule
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient , e . g . polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound , e . g . an oligomeric , polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon - to - carbon unsaturated bonds , e . g . polyureas or polyurethanes
medicinal preparations characterised by the non - active ingredients used , e . g . carriers or inert additives ; targeting or modifying agents chemically bound to the active ingredient the non - active ingredient being chemically bound to the active ingredient , e . g . polymer - drug conjugates the non - active ingredient being a modifying agent the modifying agent being an organic macromolecular compound , e . g . an oligomeric , polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon - to - carbon unsaturated bonds , e . g . polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer , polymer or dendrimer , e . g . peg , ppg , peo or polyglycerol
immunoglobulins [ igs ] , e . g . monoclonal or polyclonal antibodies against material from animals or humans
immunoglobulins [ igs ] , e . g . monoclonal or polyclonal antibodies against material from animals or humans against receptors , cell surface antigens or cell surface determinants
immunoglobulins [ igs ] , e . g . monoclonal or polyclonal antibodies against material from animals or humans against receptors , cell surface antigens or cell surface determinants from tumour cells
istituto di richerche di biologia molecolare p . angeletti s . p . a .
single - chain fv with manifold n - glycans as bifunctional scaffolds for immunomolecules .
html public
- / / w3c / / dtd html 3 . 2 final / / en
mr . tooman has nearly 20 years of industry experience and has worked extensively in diverse pharmaceutical positions including , investor communications , strategic planning , finance , marketing , and sales . while at ilex , mr . tooman managed the formation of ilexs first comprehensive strategic plan and the restructuring of the companys clinical development activities to drive the companys transformation from a drug development contract research organization into a product - driven pharmaceutical company . mr . tooman was also charged with leading the integration of ilex and genzyme , a $ 1 billion transaction that maintained the majority of ilexs operations .
before joining ilex , mr . tooman worked at pharmacia corporation where he progressed through positions of increasing responsibility in investor relations including vice president of investor relations . in this role , he was responsible for global investor relations activities and spearheaded communications with the financial community on the pharmacia and upjohn / monsanto merger . additionally , under his leadership the investor relations unit of pharmacia won four of the largest awards of distinction in investor and public relations . mr . tooman has also held various management positions in europe and japan .
mr . tooman received a master of business administration degree in finance from the university of chicago and a bachelor of arts degree in economics from kalamazoo college .
all information in this press release is as of january 5 , 2005 and the company undertakes no duty to update this information .
pegylation has successfully been used on various pharmaceutical compounds , including enzymes , peptides and antibodies , to improve their pharmaceutical properties through the chemical attachment of polyethylene glycol ( peg ) using our customized linker technology . pegylation technology employs proprietary chemical linkers designed to either release the native molecule at a controlled rate or provide permanent linkage that will maximize inherent activity of the native molecule . in some cases , pegylation can render a compound therapeutically effective , whereas the unmodified form had only limited clinical utility .
hisun is a leading biopharmaceutical group focused on improving patient wellbeing and quality of life . headquartered in taizhou ( zhejiang , china ) , the company currently employs more than 3 , 800 people . hisun’s operations strictly follow cgmp and received iso 14000 certification in 2001 . to date , more than 40 of the company’s products have passed certification by the fda ( us ) , edqm ( eu ) , tga ( australia ) , kfda ( korea ) , etc . , and are sold in more than 30 countries . the company opened its u . s . headquarters in princeton , n . j . , in 2010 . for more information , visit urltoken .
this press release contains , or may contain , forward - looking statements within the “safe harbor” provisions of the private securities litigation reform act of 1995 . all statements contained in this press release , other than statements that are purely historical , are forward - looking statements , which can be identified by the use of forward - looking terminology such as the words “believes , ” “expects , ” “may , ” “will , ” “should , ” “potential , ” “anticipates , ” “plans , ” or “intends” and similar expressions .
through this transaction , belrose pharma has added to its portfolio both “traditional” permanent pegylation and the lesser - known releasable pegylation technologies , as well as compounds based on both technologies . polyethylene glycol ( peg ) , when permanently linked to certain compounds , has a long track record of enabling high - value commercial products through sometimes dramatic improvements in in vivo circulation , toxicity , and efficacy . the lesser - known releasable pegylation technique provides a different set of clinical benefits – including several targeted release options without a corresponding reduction in potency , improved drug loading , pharmacokinetics , and efficacy , and a simplified and potentially shorter clinical path to market .
about belrose pharma inc . belrose pharma inc . ( princeton , nj ) is a specialty pharmaceutical company that operates two related businesses : ( a ) advancing development of internal clinical and pre - clinical compounds , and ( b ) product development for third party customers seeking to improve both early clinical and mid - lifecycle products using a range of technologies including customized linker technology® . belrose combines a new senior commercial management team with a core technical team previously involved in development and commercialization efforts using customized pegylation linker technologies . further information about belrose can be found on the company’s website at urltoken .
moody’s daily credit risk score is a 1 - 10 score of a company’s credit risk , based on an analysis of the firm’s balance sheet and inputs from the stock market . the score provides a forward - looking , one - year measure of credit risk , allowing investors to make better decisions and streamline their work ow . updated daily , it takes into account day - to - day movements in market value compared to a company’s liability structure .
* copyright © 2018 insider inc . and urltoken gmbh ( imprint ) . all rights reserved . registration on or use of this site constitutes acceptance of our terms of service , cookie policy , and privacy policy . disclaimer | commerce policy | made in nyc | stock quotes by urltoken need help ? contact us !
this company is compared to stocks in the same industry . it is sorted by largest to the smallest market value . feel free to change the stock symbol and select the compare button .
this row includes the target price and the current last sale ' s ( cls ' ) percent of the target price ( tp ) . the target price is defined as the analyst estimated 1 year target price . the cls ' percent of tp calculation is ( current price / target price ) * 100
and the % change of the 52 week high from the current last sale . the 52 week high is defined as the highest end of day value for the past year . the color coding assigns a value of ' very positive ' to ' very negative ' . the color key , below , indicates the assigned values and a possible explanation for the rating . however , it is important to note that each value should be looked at in combination with other factors . the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision . advice from a securities professional is strongly advised . please
neutral : 10 to 15 % ( this means the stock is trading at a level that doesn ' t provide any clear signal for price movement . )
negative : 16 % to 30 % ( this indicates that the % decrease is at a level that may indicate a stock that lacks support for a higher stock price ) .
more negative : 31 to 60 % ( this indicates that the % decrease is at a level that may indicate a stock that lacks support for a higher stock price ) .
very negative : 61 % and below ( this indicates that the % decrease is at a level that may indicate a stock that lacks support for a higher stock price ) .
and the % change of the 52 week low from the current last sale . the 52 week low is defined as the lowest end of day value for the past year . the color coding assigns a value of ' very positive ' to ' very negative ' . the color key , below , indicates the assigned values and a possible explanation for the rating . however , it is important to note that each value should be looked at in combination with other factors . the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision . advice from a securities professional is strongly advised . please
. the beta is defined as a measure of the volatility of a stock relative to the overall market . a beta of less than one indicates lower risk than the market . a beta of more than one indicates higher risk than the market . urltoken uses the s & p 500 as the underlying index to measure the overall market for beta . the color coding assigns a value of very positive to very negative . the color key , below , indicates the assigned values and a possible explanation for the rating . however , it is important to note that each value should be looked at in combination with other factors . the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision . advice from a securities professional is strongly advised . please
. the days to cover is calculated as the aggregate short interest for the month divided by the average daily share volume traded for the period between short interest settlement dates . days to cover is also referred to as ' short - interest ratio ' . the term ' days to cover ' was coined to indicate how many days it will take short sellers to cover their positions if the price of a stock rises . some investors see a high short interest as an opportunity ; this is referred to as ' short squeeze ' . visit investopedia for more information about
. the color coding assigns a value of ' very positive ' to ' very negative ' . the color key , below , indicates the assigned values and a possible explanation for the rating . in this instance the rating is assuming that the person is the ' short seller ' . however , it is important to note that each value should be looked at in combination with other factors . the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision . advice from a securities professional is strongly advised . please
please note : the sec has issued technical ammendments to the emergency short sale order that provided listing exchanges with guidance regarding which securities are covered by the order . nasdaq has posted a list of inculded financial firms for our market as well as a consolidated list for all exchanges . nasdaq continue to post updated lists on this page daily until the expiration of the emergency order .
very positive : 1 and lower ( this indicates that the stock would take less than a day for short sellers to cover their positions .
positive : 1 . 1 - 1 . 5 ( this indicates that the stock would take slightly longer than a day for short sellers to cover their positions .
neutral : 1 . 6 - 2 ( this indicates that the stock would take up to two days for short sellers to cover their positions .
negative : 2 . 1 - 3 ( this indicates that the stock would take more than a two days for short sellers to cover their positions .
more negative : 3 - 8 ( this indicates that the stock would longer for short sellers to cover their positions .
very negative : 9 and above ( this indicates that the stock would take much longer for short sellers to cover their positions .
. the p / e is defined as the stock analysis statistic in which the current price of a stock ( today ' s current last sale price ) is divided by the reported actual ( or sometimes projected , which would be forecast ) earnings per share of the issuing firm ; it is also called the ' multiple ' . visit urltoken to read about
. the color coding assigns a value of ' very positive ' to ' very negative ' . the color key , below , indicates the assigned values and a possible explanation for the rating . a low p / e might indicate a number of negative factors , including , but not limited to projected lower earnings . however , it is important to note that each value should be looked at in combination with other factors . the stock comparison page should serve as one among many informational tools for comparing stocks and should not be the only basis for a buy or sell decision . advice from a securities professional is strongly advised . please


data management inc. ( dmi ) is an american corporation in san angelo , texas .

it was founded by jorge ellis in 1988 and specializes in business software development , particularly for time and labor management .

its flagship product is timeclock plus , a computerized time and attendance system .

the company originally developed the " one number delivery system " software for food delivery services .

through his business with retailers , ellis discovered a growing need to track time and attendance : " ' no one could tell me at any given minute what the [ labor ] costs were .

i decided to develop a software package that would give a 24-hour picture . ' " the system developed by dmi , called timeclock plus , was written for companies as small as five employees or as large as 750 and larger .

in april 2011 , the san angelo standard times reported that about 50,000 companies were using the system including boeing , harley davidson , ford motor company , dial , and sara lee .

data management inc .

since 1982 , management data , inc . has specialized in insurance administration software solutions .
complete revenue cycle management service , claims and insurance processing , ar management , monthly & yearly cashflow and accounting management .
© 2014 – 2018 data management , inc . all rights reserved . | site map | privacy policy | terms of use
digipass for apps featuring cronto technology and rasp capabilities , vasco data security international , inc .
bi , visual analytics , and data discovery : johnson & johnson consumer companies , inc .
unify your multi - cloud applications and data for management ease . unlock deep data intelligence to address security , governance and compliance .
emerging technologies and methods : ultra mobile , inc . solution sponsor : denodo technologies
richmond , bc , march 21 , 2017 - - ( t - net ) - - ze powergroup inc . ( ze ) , a leading software company specializing in enterprise data management and analysis solutions for energy and commodities markets , today announced it has won the commodity business awards 2016 in the category of data management .
at rubrik , we’re obsessed with innovation . we thrive on solving the biggest data management challenges in an unconventional and radically…
this data management award demonstrates ze ' s continuous dedication and foresight in delivering innovative best - in - breed data management , analysis and business intelligence technology to the commodities and energy industry sectors
, stated the company in a press release .
data management , inc . , develops specialized printed products and software that organizations of all kinds use to document critical information in ways that save them time , improve their effectiveness , promote their business , and improve security .
ze ' s flagship solution , zema aggregates live commodity and energy data from over 705 unique data providers and over 8 , 500 data feeds .
60 % tco savings and rubrik software at remote sites with single pane of management .
developed by data management inc . , timeclock plus is available as a browser - based application suite and records employee hours for payroll while providing real - time labor reporting functions to more than 60 , 000 organizations worldwide . as a recipient of numerous awards . timeclock plus is a leading provider of time and attendance and workforce management solutions .
“data management category is a highly competitive category and to receive this award is an honor and a testament to our staff ' s continuous dedication in delivering award winning solutions to our clients . ” says dr . zak el - ramly , president and ceo of ze powergroup inc .
rubrik customer , daniel king , vp of it at frost bank , explains why he replaced legacy backup for modern data management built for speed , savings , and cloud .
with access to ze ` s extensive global data library , zema enables traders , risk managers , and business analysts working in the energy and commodities markets worldwide to perform collaborative analysis that goes well beyond the scope of traditional data management systems . zema is also designed to integrate data and analysis seamlessly with third - party downstream systems including erp , etrm , and bi tools , along with more recently feeding market data into clients ' big data lakes , such as hadoop .
when dealing with lots of data , it ' s important to start with a strong , solid foundation , while keeping the overall and end vision in mind . dmi specializes in accessing , protecting and enhancing the value of companies ' data . the data sources we manage include internal data ( transactions , pricing , customer ) , mobile devices , the web , social media and a growing list of automated sensory technologies . our experts assess data management needs , and then deploy people and process to effectively initiate data migration , quality and governance programs .
for more than 20 years , tdwi has been raising the intelligence of data leaders and their teams with in - depth , applicable education and research , and an engaged worldwide membership community . accelerate the success of your data management and analytics projects—and your career—with tdwi .
ze and zema are trademarks of ze powergroup inc . all other company and product names may be trademarks of the respective companies with which they are associated .
innovations in big data , business intelligence , data warehousing , and analytics implementations to be recognized at tdwi anaheim , august 6 - 11 in southern california .
ze is a technology leader providing customers with software and services that transform decoupled and fragile data into streamlined , transparent , secure , and automated business processes . zema , ze ' s award - winning flagship software , is a comprehensive data management and business process automation software solution . with its unparalleled data library , analytical functionalities , curve management , and integration capabilities , zema offers a modular , end - to - end , automated solution for clients of all sizes , operating in any industry .
to get the most out of your data , you need a solid plan .
deliver speedy backups for your physical , virtual , and cloud applications and data .
that means instant recoveries , hands - free management , automated workflows , easy cloud adoption , and hard dollars saved for other projects .
fimmas , mdi ' s flexible insurance marketing , management , and administration system , provides a full - function individual and group insurance administration system .
people always say that clean data is valuable data . use our marketing database , and we can clean , validate , deduplicate and segment your donor data . when you’re ready to launch your next direct - mail campaign , rest assured that your segments are ready to go .
get a 360º view of your donors by joining your data with public and commercially available datasets .
insurance administrators , inc hosts , manages and maintains fimmas policy and client administration software . you can elect to run the software on iai ' s server , the cloud , or your server , with the server located at your office , or connected remotely to your office from iai ' s data center , or remotely from the cloud .
the intouch crm provides a powerful , holistic platform for your organization ' s data - driven campaigns and operations .
through innovative software products and analytical services , we help nonprofits store , segment and use their data to drive fundraising success .
easy - to - use visitor software for quick sign - in and badging , reliable data access , and convenient reporting .
unlock cloud for dr or test / dev . migrate data to and from the cloud . no vendor lock - in .
since 1997 , the commodity business awards have been rewarding excellence throughout the commodity and energy supply chain in trading , risk management , structuring , finance , research , advisory , logistics , legal , and specialist technology .
tdwi ' s best practices awards identify and honor companies that demonstrate excellence and innovation in developing , deploying , and maintaining bi , dw , and related data management ( dm ) applications . all nominated solutions were evaluated by tdwi analysts and facultyon business impact , maturity , innovation , and relevance in their field to select award winners from the applicants .
your organization’s fundraising and donor data lives in a lot of places . while it’s smart to use a lot of tools to deliver on your mission , reporting can be nearly impossible when your data lives in silos . we’ve built powerful integrations with dozens of popular marketing and fundraising tools . these integrations allow us to bring all of your data together into a single database , which makes reporting and segmentation a breeze .
deploy rubrik to protect , manage , and recover your applications and data on - prem , at the edge , or in the cloud .
without having the timeclock plus data so easily accessible , we couldn ' t be as cost competitive , and that is critical to our business .
can you instantly recover from a disaster , data loss , or a cyber attack like ransomware ? meet rubrik . it chaos has met its match .
why syneos health ? join a game - changing company that is reinventing the way therapies are developed and commercialized . created through the merger of two industry leading companies , inc research and inventiv health , we bring together more than 22 , 000 clinical and commercial minds to create a better , smarter , faster way to get biopharmaceutical therapies into the hands of . . .
about tdwi for 20 years , tdwi has helped individuals and teams transform data with intelligence through a comprehensive portfolio of business and technical education and research . the in - depth , best - practices - based knowledge tdwi offers can be quickly applied to develop world - class talent across your organization’s business and it functions and to enhance analytical , data - driven decision making and performance . tdwi advances the art and science of realizing business value from data by providing an objective forum where industry experts , solution providers , and practitioners can explore and enhance data competencies , practices , and technologies . tdwi presentssix major conferences as well as topical seminars , onsite education , membership , certification , live webinars , resource - filled publications , industry news , and in - depth research . see urltoken or follow us on twitter @ tdwi .
seattle , wa , july 11 , 2017— tdwi , the premier source for in - depth education and research on all things data , is pleased to announce the 2017 winners of its annual best practices awards .
dmi specializes in the business of big data . our methodology begins by first understanding your business goals and then pairing your vision with our end - to - end capabilities and best practices , providing expertise from the foundation and architecture to the predictive insights and visualizations . we help our clients scope and build out their big data environments in order to tap new revenue streams , improve customer loyalty and generally make better business decisions .
a good business strategy gives an organization a long - term plan of action and creates a competitive advantage . our expertise in big data and analytics strategy helps businesses leverage core competencies to drive sustainable growth and profitability .
a radically simple user experience is driven by powerful intelligence under the hood . rubrik is a self - learning system built to index massive amounts of data while globally executing tasks in a fault - tolerant and efficient manner .
struggling to get the reports your team needs ? we can work with you to analyze your data , build any reports or visualizations your team needs , develop a strategy for improving fundraising kpis , and monitor your organization’s progress toward key goals .
about 1105 media 1105 media , inc . , is a leading provider of integrated information and media in targeted business - to - business markets , including specialized sectors of the information technology community ; industrial health , safety , and compliance ; security ; environmental protection ; and home healthcare . 1105 ' s offerings span print and online magazines , journals , and newsletters ; seminars , conferences , and trade shows ; training courseware ; and web - based services . 1105 media is based in chatsworth , ca , with offices throughout the united states .
“once again , it’s a privilege to recognize individuals and organizations who are driving innovation through data and analytics” said meighan berberich , president of tdwi . “the best practice awards attract an incredible diversity of innovative solutions and the winners are truly the best of the best . i’m excited to present these awards to the winning companies this august” .
“within the commodities and energy sector , our technology , zema™ , is here to help businesses own , control and amplify the value derived from their data through the automation of collection , analysis and integration . we give our clients all the tools that allows them to understand market dynamics to make better decisions to reduce risk faster than anything else out there . ”
we drive performance by providing decision makers with actionable insights based on their unique business objectives . by scoping and building descriptive and predictive models , we help our clients anticipate future trends , identify untapped opportunities and recognize potential risks . with years of experience across multiple industry verticals , our teams of analytical architects , solution leads and statisticians deliver compelling , data - driven insights that deliver measurable value .
html public
- / / w3c / / dtd html 4 . 01 transitional / / en
oil prices mixed on canadian outage update , u . s . sanctions on iran
pre - open movers 07 / 09 : ( mbvx ) ( hele ) ( grpn ) higher ; ( ctic ) ( pets ) ( pg ) lower ( more . . . )
pre - open movers 07 / 06 : ( bbox ) ( biib ) ( rgse ) higher ; ( rgls ) ( gci ) ( psmt ) lower ( more . . . )
after - hours stock movers 07 / 05 : ( cveo ) ( vc ) higher ; ( rgls ) ( psmt ) lower ( more . . . )
pre - open stock movers 07 / 05 : ( xplr ) ( fcau ) ( mu ) higher ; ( zyne ) ( amsc ) ( clne ) lower ( more . . . )
pre - open movers 07 / 03 : ( jnp ) ( avxl ) ( ayi ) higher ; ( glncy ) ( dal ) ( aal ) lower ( more . . . )
annual list showcases the 50 most promising education technology solution providers 2015 ; timeclock plus® makes it to cio review ' s 50 most promising education technology solution providers list for its expertise in providing solutions for the education technology landscape .
get instant alerts when news breaks on your stocks . claim your 2 - week free trial to
fremont , calif . , nov . 18 , 2015 / prnewswire / - - cio review ( urltoken ) has chosen timeclock plus for its 50 most promising education technology solution providers 2015 . the positioning is based on an evaluation of timeclock plus offerings for the education technology landscape .
the annual list of companies is selected by a panel of experts and members of cio review ' s editorial board to recognize and promote technology entrepreneurship .
timeclock plus has been on our radar for some time now for stirring a revolution in the education technology landscape , and we are happy to showcase them this year due to their continuing excellence in delivering top - notch technology - driven solutions ,
said harvi sachar , publisher and founder , cio review .
timeclock plus solutions continued to break new ground within the past year benefiting its customers around the globe , and we ' re excited to have them featured on our top companies list .
timeclock plus is honored to be recognized by cio review ' s panel of experts and thought leaders ,
said vice president of marketing and quality assurance , scott turner .
cio review constantly endeavors to identify
the best
in a variety of areas important to tech business . through nominations and consultations with industry leaders , our editors choose the best in different domains . education technology edition is the listing of 50 most promising education technology solution providers 2015 in the u . s .
can ' t see the text ? click here to refresh the image . what ' s this ?
our analytics products and reporting platform provide you with robust tools to plan and monitor campaign progress .
whether you ' re meeting your donors at the mailbox or at the inbox , our platform will deliver the same powerful experience .
dive deep into your digital and direct mail campaigns . measure performance kpis , track subsequent net lifetime values , learn from past campaigns , and build reports and visualizations to monitor performance .
securely process and manage credit card and other transactions with an easy - to - use virtual terminal that integrates seamlessly with paypal , stripe , urltoken and more .
draw key insights from powerful reports and simple visualizations . discover valuable statistics about your donors and their giving habits . easily export and share reports with anyone .
easily find the records you’re looking for with advanced , lightning - fast search . manage donors and their transactions , promotional history , planned giving and more with ease .
easily manage your fundraising tasks and projects to insure no donation goes unacknowledged and outreach work gets done on time . collaborate with your team to fundraise more effectively .
connect dmi’s powerful fundraising tools directly to your existing salesforce account . kiss those one - size - fits all salesforce add - ons “goodbye” with no costly development time or messy code required .
this website uses cookies and other tracking technologies to help us deliver a better user experience to our guests . if you do not agree to have your activity tracked , please navigate away from this website and no further tracking will occur .
if you ' re the kind of person who wakes up every day ready to help others and reinvent the world , you belong here . dmi isn ' t just a job – dmi is where you ' ll do your life ' s work .
our people are given the freedom to explore , experiment , and innovate on behalf of our partners . if the idea of starting a bold adventure without a map excites you , come join us .
we’ll work quickly to review your résumé . if we believe you’re a good fit for an open position , we’ll be in touch soon .
by hand or by computer , provide fabric - friendly adhesive badges that change color overnight to prevent reuse .
we make great impressions on our customers by producing high - value , innovative solutions that make a difference .
visitor pass solutions has been designing and producing visitor badges for companies across america since 2003 . since our specialty is . . .
protecting the security of your employees , equipment , and business secrets requires an understanding of many variables and having the r . . .
providers of high - tech security solutions , which seem to always get the most attention , often try to sell you on all the bells and whis . . .
we will be exhibiting at asi chicago 2018 in chicago , il from 7 / 24 / 2018 - 7 / 26 / 2018 . stop by booth # 536 and see our visitor pass soluti . . .
we will be exhibiting at 2018 fall idn summit in phoenix , az from 9 / 17 / 18 - 9 / 19 / 18 . come see our visitor pass solutions . click here for . . .
we will be exhibiting at the global security exchange ( formerly asis 64th annual seminar and exhibits ) in las vegas , nv from 9 / 23 / . . .
knowing who comes to visit your facility , how long they stayed , and who they visited are important components to know in order to keep a building secure .
fimmas is a complete , integrated system for the support of a wide range of group and individual insurance products . the same programs , screens , menus , and procedures support life , health , and annuity products .
from designing a web - based front end for remote agent entry of insurance applications , to helping design a commission plan , to installing a turnkey insurance administration system , mdi can help you plan and implement an effective , integrated insurance system strategy .
we help you explore new ways to approach business needs to find your most effective alternatives . has your marketplace changed ? does technology change your relationship with your customer ? are certain procedures no longer appropriate for a different market or product ? we use our experience to help you find your best total business solution . you decide the best blend of mdi resources to complement the skills and availability of your in - house staff .
fimmas runs in a client / server environment , with a linux , unix , or windows operating system using industry - standard network protocols and pc workstations .
the primary tool used for fimmas development is appx , a platform - independent , comprehensive runtime , database , and high - level programming environment . source code is optionally available for in - house modification .
extensive user exits are available throughout fimmas to call programs written in current industry - standard languages ( like c , c + + , rust ) , as well as legacy languages like cobol , fortran , and basic . this simplifies the exchange of information and integration of functions between fimmas and specialized , internally - developed applications .
for the past 30 years , we have worked to provide the highest quality and best in class automated time and attendance solution on the market .
timeclock plus is defined by a specific culture that stands out amongst the competition , a culture you ( our customers ) have helped create .
we believe that our time is best spent with you , and as the industry changes , we are involved to evolve with you . the standards our customers set are matched by our seamless , innovative v7 software , designed to help you better manage labor costs , reduce compliance risk , and easily adapt to dol requirements .
whether you own a company of thousands or just starting off as a small business , we have a customizable solution tailor made to fit . our express , standard , and professional software packages are designed with you mind , and guaranteed to help you optimize your workforce .
over the years , our commitment to attempt to fulfill the needs of each and every customer has resulted in over 60 , 000 organizations clocking over 5 million users across the country every day . from our mobile solutions to biometric clocks , we have created a scalable and comprehensive solution to optimize your time and attendance needs .
would you like to join our team ? take a look at the positions we have to offer , then give us a call or send us your resume .
it has been our experience that the employees at timeclock plus really care about their customers and make every attempt to keep them happy .
it ' s not difficult to get help from timeclock plus and the response times are quick , which makes my life a whole lot easier . i ' m just pleased that when i go to chat with someone online they are there right away , respond quickly , and can solve my problems .
thanks to tcp ' s superior functionality , all i had to do was set up my job codes and i was rolling .
timeclock makes it so easy for me to call and get questions answered quickly and easily . i never have a problem getting someone to answer when i call , and help is immediate . timeclock is one of the best decisions i have made for my office .
as an employee , i like that i have the ability to manage my own time and keep track of my hours day over day . and see adjustments as necessary .
great customer service , saved us a lot of time and effort . timeclock plus ! it ' s the only way to go .
timeclock plus has been a great product . it is very easy to use and keep track of times . very user friendly !
my experience with your service dept . has always been positive and i ' m treated with respect . i ' m not sure how you choose your techs but you are doing something right because i never dread calling for help , not when i know the person on the other line will be so friendly and helpful .
it ' s easy to use ; i love that i can easily check to see when i clocked in or out , and that i can see how many hours i ' ve worked over the course of the week .
this system is very user - friendly and easy to use in every regard . i have not once been disappointed in using this system .
i always have a good experience when working with your customer support . i would recommend timeclock plus to anyone because of your customer support .
we use cookies to ensure that we give you the best experience on our website . if you continue to use this site we will assume that you are happy with it .
appointment scheduling , patient demographics , patient charting , financial accounting with monthly / yearly reporting , insurance / claims processing , etc .
fully - certified ehr system modules including erx , emar , inpatient / outpatient demographics , electronic lab testing , electronic messaging , hippa - compliance and security .
audio - video virtual - visit , patient consulting platform with session recording for future retrieval and eduction including family participation during patient consultation .
not ready to apply ? take just a minute to sign up for job alerts .
please enter your email to download the submission forms . we will never pass on your details ( but we may email you to let you know when the deadline is looming ) .
the best overall education solution represents the product with the highest scores of both rounds of judging . all finalists are automatically entered for this award .
javascript is disabled or not supported by your web browser . javascript is required for the proper function of the t - net website .
hosted by commodities now , the commodity business awards reward talent and excellence in commodity markets .
ze powergroup® was established in may 1995 by dr . zak el - ramly as a strategic consulting and software development firm to serve the emerging needs of energy markets in transition .
registration on or use of this website constitutes acceptance of our terms of use .
tdwi best practice award recipients will be honored at the tdwi anaheimconference , taking place august 6 - 11 at the disneyland hotel in anaheim , ca . representatives from each company , along with their solution sponsors , will receive awards during the opening of the event .
qualified members of the media can request interviews with meighan berberich , tdwi president ; fern halper , vice president and senior director of research for analytics ; or request press credentials for tdwi anaheim by contacting matt carter , tdwi vice president of marketing , at mcarter @ tdwi . org .
effective business intelligence and visualization platforms play a critical role in getting meaningful and actionable information into the hands of business users . our user experience and visualization experts specialize in transforming complexity into a consumer - grade , user - friendly and intuitive bi solution that leads to increased user adoption , roi and productivity .
one powerfully simple solution across your legacy , virtual , and cloud - native applications .
legacy to new - age . on - prem to cloud . we have you covered . build for today and tomorrow at your own pace . all with breakthrough
fastest recoveries . on - prem to cloud . powered by a smart engine .
meet polaris gps . one easy - to - use interface for global visibility and control .
rubrik announces alta 4 . 2 release , extending leadership in the enterprise hybrid cloud